Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A Phase 2 Single Arm Trial of Cabozantinib in Patients with28 passages
• A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer Alistar Angela MD12Morris29 passages
• Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial de Boer51 passages
• Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial Wakelee38 passages
• An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression Beaver35 passages
• Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial Judson Ian ProfMDIan.Judson@icr.ac.uka*Morden45 passages
• Centre, Cambridge, UKCancer and Leukemia26 passages
• Centre, London, UKs Department of Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UKt Department of Oncology, Christie Hospital, Manchester, UKu Department of Oncology,60 passages
• Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 7RU, UKCorrespondence to: Prof47 passages
• Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UKp Cancer44 passages
• Chromatin organisation and cancer prognosis: a pan-cancer study Kleppe Andreas PhDafgAlbregtsen Fritz ProfCand RealafVlatkovic Ljiljana MDbPradhan Manohar PhDagNielsen Birgitte PhDagHveem46 passages
• CollaborativeAchuthan R51 passages
• Council Clinical Trials Unit at UCL, London, UKd Centre for Surgical Research, University of Bristol, Bristol and University Hospitals55 passages
• Council Clinical Trials Unit at University College London, London, UKg Department of Preventive Medicine, Keck Medical Canter at the University of Southern California, Los44 passages
• Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial Cunningham David ProfMDdavid.cunningham@rmh.nhs.uka*Stenning49 passages
• Council of Australia, Swedish Cancer Society, Medical Research40 passages
• Council, Stockholm Cancer Society, and Cancer37 passages
• Council, Swedish Cancer Society, NETSCC, and Cancer61 passages
• Design Service South West, Bristol, UKd South Devon45 passages
• Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial Anderson41 passages
• Fund, National Institutes of Health, California Cancer Research Program, California Department of Health Services,36 passages
• Fund, and the National Institute for Health and Research Biomedical Research Centre at The Royal29 passages
• Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial Davies Andrew ProfPhDabCummin53 passages
• Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study Copson42 passages
• Germline Genetic Variation in ETV6 and Risk of Childhood Acute Lymphoblastic Leukemia: a Systematic Genetic Study Moriyama Takaya MDab*Metzger27 passages
• Grant from Cancer49 passages
• Health Technology Assessment, Cancer45 passages
• Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial Zelenetz48 passages
• Institute Haematological Oncology Clinical Studies Group a Institute of Cancer Research, Royal32 passages
• Lancet Oncol1883 passages
• Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial Jackson56 passages
• Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial Drayson47 passages
• Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial Shaw39 passages
• Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial Sharma Padmanee Prof.MDCallahan36 passages
• ORGAN PRESERVATION FOR CLINICAL T2N0 DISTAL RECTAL CANCER USING NEOADJUVANT CHEMORADIOTHERAPY AND LOCAL EXCISION: RESULTS OF A MULTICENTER PHASE 2 STUDY Garcia-Aguilar Julio ProfMD1Renfro30 passages
• Oncology, King's College London, Guy's Hospital, London, UKc Academic Oncology, Guy's Hospital, London, UKd City Hospital, Department of Histopathology, Nottingham, UKe Cancer26 passages
• Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer Shaw33 passages
• Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study Koo Minjoung Monica PhDmonica.koo@ucl.ac.ukab*Swann Ruth PhDbcMcPhail Sean PhDabAbel28 passages
• Prognostic Value of Medulloblastoma Extent of Resection After Accounting for Molecular Subgroup: An Integrated Clinical and Molecular Analysis Thompson32 passages
• Prospective Randomized Trial of Post-operative Stereotactic Radiosurgery versus Observation for Completely Resected Brain Metastases Mahajan32 passages
• Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study Bright52 passages
• Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial Lyon57 passages
• Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study Perl52 passages
• Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort Waszak45 passages
• Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)Baumert40 passages
• The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016 India State-Level Disease Burden Initiative Cancer CollaboratorsDhillon53 passages
• The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017 GBD 2017 Childhood Cancer CollaboratorsForce49 passages
• UK Centre, MRC IGMM, Edinburgh, UKc The38 passages
• UK and UCL Cancer Clinical Trials Centre, London, UKe University of Liverpool and Clatterbridge Cancer Centre, Liverpool, UKf The Royal50 passages
• UK and UCL Cancer Trials Centre, London, UK* Correspondence to: Dr Beatrice Seddon, London Sarcoma Service, Department of Oncology, University College London52 passages
• UK and UCL Cancer Trials Centre, University College London, London, UK* Correspondence to: Mr Allan Hackshaw, Cancer37 passages
• UK and UCL Cancer Trials Centre, University College London, London, UKCancer39 passages
• UK, AstraZeneca, Prostate49 passages
• UK–MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK* Correspondence to: Dr32 passages
• Unit in Cancer Awareness, Screening and Early Diagnosis, Queen Mary University of London, Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1M 6BQ, UKCorrespondence to: Prof21 passages
• Unit, University of Warwick, Coventry, UKf University Hospitals44 passages